Reviewer's report

Title: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Version: 3 Date: 24 March 2013

Reviewer: Howard Burris

Reviewer's report:

1) no major revisions

2) minor -- would be helpful to explain by relative dose intensity or dose density, the comparison of delivered dose between q 3 week and weekly cabazitaxel.

3) discretionary -- an explanation would be helpful around the choice of the unusual 5 week cycle, when most weekly regimens are explored continuously or with a 3 on and 1 off q 4 week schedule. It would also be of interest to read in the discussion the comparison of the relative dose intensity achieved between q 3 week and weekly dosing of cabazitaxel and the author’s opinions on the associated merits of each schedule, which seem more similar than dissimilar. Lastly, with the weekly schedule of docetaxel in the treatment of prostate cancer, those results appeared inferior compared to q 3 week doing in a randomized registration trial. As cabazitaxel is also approved in this disease setting, the author’s thoughts on the potential use of weekly cabazitaxel for those patients would be useful to the reader.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

No financial or competing interests are a conflict. I own no shares in Pharma or biotech companies except as part of diversified mutual funds.

I declare that I have no competing interests.